Navigation Links
'1 pill can kill': Effects of unintentional opioid exposure in young children
Date:8/28/2013

Cincinnati, OH, August 29, 2013 -- Medication poisonings among children are an important public health problem. During 2010-2011, an average of 1500 children under 6 years of age was evaluated in emergency departments each year due to unintentional exposure to buprenorphine. Ingestion of strong opioids, such as buprenorphine, can cause central nervous system depression, respiratory depression, and death in young children. In a new study scheduled for publication in The Journal of Pediatrics, researchers study how young children are gaining access to buprenorphine, as well as the effects of unintentional exposure to its different formulations.

Buprenorphine (or the buprenorphine-naloxone combination form), usually sold as a tablet or film strip, is used to treat adults who are addicted to opioids, such as prescription pain medication and heroin. Tablets typically are dispensed in 30-day supply bottles with child-resistant caps, and film strips are dispensed in single-dose, child-resistant foil packs. Dr. Eric Lavonas and colleagues from the Rocky Mountain Poison and Drug Center, the University of Colorado School of Medicine, the University of Oklahoma, Integris Baptist Medical Center, Degge Group, and Venebio Group studied 2380 cases of unintentional exposure to buprenorphine in any form involving children under 6 years of age. The average age of the children was 2 years. Common effects of buprenorphine exposure were lethargy, respiratory depression, miosis (small pupils), and vomiting. Although most children had good outcomes, 587 children were admitted to the intensive care unit and 4 children died.

The researchers found that children were 3.5 to 8.8 times more likely to accidentally ingest the tablets as have unintentional exposure to film strips; 95% of cases involved tablets. In 57% of the cases, at least one root cause for the exposure was identified: 415 cases involved medication stored in sight, in 110 cases the child accessed the medication from a bag or purse, and in 75 cases the medication was not stored in the original packaging. Although most exposures were in the child's own home, 5% of exposures occurred while the child was being watched by another caregiver.

Buprenorphine can be helpful in adult patients who are struggling with addiction issues, but it should not be accessible by children because even a single dose can be life-threatening. Therefore, it is important for all caregivers to be especially vigilant in keeping medications in their original packaging and up, away, and out of sight of children. Although this study focused on just one medication used in a specific population, other more widely used medications, such as those used to treat high blood pressure or diabetes, can be as harmful in young children. According to Dr. Lavonas, "This study underscores the value of providing medications that are particularly dangerous when taken by children, in single dose, child resistant packaging." This approach is likely to be more effective at reducing unintentional exposure than additional efforts at education.


'/>"/>

Contact: Becky Lindeman
journal.pediatrics@cchmc.org
513-636-7140
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Study adds lung damage to harmful effects of arsenic
2. New tests for determining health and environmental effects of nanomaterials
3. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
4. Researchers study seleniums effects on horses
5. Study explores effects of review setting on scientific peer review
6. Rapamycin: Limited anti-aging effects
7. Key target responsible for triggering detrimental effects in brain trauma identified
8. Adverse effects of phthalates on ovarian response to IVF
9. Time is of the essence for reducing the long-term effects of iron deficiency
10. Patients use OTC NSAIDs even when they have a high risk of serious side effects
11. Hidden effects of climate change may threaten eelgrass meadows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):
(Date:9/25/2017)... UT, and Portland, OR (PRWEB) , ... ... ... CallTower , an industry-leading Unified Communications (UC) and Collaboration company, and ... in real-time, announced today a strategic alliance to extend CallTower’s Unified Communication ...
(Date:9/22/2017)... ... September 22, 2017 , ... HOLLOWAY ... a booth at premier packaging event PACK EXPO International in Las Vegas from ... Manufacturers Institute (PMMI). , At this year’s PACK EXPO at the Last Vegas ...
(Date:9/21/2017)... ... 2017 , ... Vixiar Medical announced today that it will ... The LaunchPort™ Accelerator at the City Garage in Port Covington. The LaunchPort™, and ... services to its Residents. , Vixiar Medical recently closed a $1.5 million ...
(Date:9/21/2017)... and London UK (PRWEB) , ... September 21, ... ... DrugDev , a QuintilesIMS company, who enable the world’s most progressive pharma and ... over 2,000 clinical trials at top pharma and biotech events in Q4. , ...
Breaking Biology Technology: